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BACKGROUND
On 8 June, 2015, London, a workshop on bacteriophage therapy
was organized by the European Medicines Agency (EMA). About
60 delegates from various stakeholders (participants belonged
to public bodies such as WHO, ECDC, WAAAR, national health
agencies from different European countries, politicians, journal-
ists, clinicians, researchers, including six members of P.H.A.G.E.,
as well as private companies.) were convened to participate,
with the workshop broadcast on the EMAwebsite. Why did EMA
organize a workshop on bacteriophage therapy? The answer is
the emergency to find solutions to overcome the global antibi-
otic crisis and the unfortunately corresponding lack of signifi-
cant interest in bacteriophage therapy. The past two decades,
public health agencies reported on the dramatic increase of
drug-resistant pathogens, a worrisome situation leading the
World Health Organization (WHO) to declare a new ‘preantibi-
otic era’ in its 2014 surveillance report (http://www.who.int).
In the USA, based on data collected in 2009, over 20 000 an-
nual deaths were ascribed to the lack of effective antibiotics.
Comparably in Europe, we estimate that more than 100 000
people worldwide die annually. The situation gets worse: a re-
cent study mentions that in France about 13 000 people died
in 2012 (http://www.invs.sante.fr). Worldwide, the estimation
is rising to 700 000 deaths annually, and therefore G7 Health
Ministries recently called for a global ‘One Health’ approach
(https://www.g7germany.de). Future predictions are alarming,
with 10 million people estimated to die from resistant microor-
ganisms in 2050 if nothing changes (Carlet 2015).
FROM FIXED ANTIBIOTICS TO FLEXIBLE
BACTERIOPHAGES?
Bacteriophage therapy is nearly 100 years old and was first in-
troduced in France and Belgium a decade before the discovery of
penicillin by A. Fleming. After an initial worldwide interest (in-
cluding from the pharmaceutical industry), bacteriophage ther-
apy was abandoned in the Western World in the 1940s due to
the advent of more convenient broad spectrum antibiotics and
the unreliability of the early bacteriophage preparations. Mean-
while, in the former Soviet Union bacteriophage therapy was
further developed. Over the past century, thousands if not mil-
lions of patients have been treated with bacteriophages and to-
day two phage therapy centers, in Poland and in Georgia, are
still operational. Interestingly, in Poland—a European Union (EU)
Member State—bacteriophage therapy is currently used to treat
antibiotic-resistant bacterial infections. Such treatment is per-
formed under the umbrella of Article 35 of the Declaration of
Helsinki (reading ‘treatment of a patient, where proven inter-
ventions do not exist’) and is done with the consent of the pa-
tient (Mie¸dzybrodzki et al. 2012). With an increasing number of
patients who could benefit from bacteriophage therapy, the cur-
rent situation, in which some EU patients have access to an
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alternative treatment while others do not, is not sustainable and
should be dealt with on an EU level. It is certainly not the first
time that medicine has faced health inequalities that need to
be solved at a political level. Examples are currently authorized
drugs such as antiretroviral therapy for HIV or vaccines for avian
influenza patients and more recently experimental treatment
for Ebola virus, for which access and availability were worked
out politically to deal with major public health issues.
Bacteriophage therapy is facing several challenges. First, due
to an insufficient interest from establishedWestern pharmaceu-
tical companies, no commercial bacteriophage preparations for
human use are currently available in the EU or in the United
States. Second, competent medical authorities had not antic-
ipated that bacteriophage-based products would benefit from,
or even need, adapted requirements for production, quality and
safety. This has led to a substantial delay in starting the first
multi-center phase II clinical trial funded by the European Com-
mission (www.phagoburn.eu). Third, the evolving nature of bac-
teriophages, allowing them to infect evolving bacteria, as well
as the ingenious therapeutic feature of being self-replicating
and self-limiting at the site of infection (one main advantage
of bacteriophages over antibiotics), makes them very differ-
ent from any other known pharmaceutical product. Finally, the
ability to select bacteriophages that can specifically target the
infecting bacteria in individual patients is opening the door
for sustainable tailor-made approaches, which are outside of
the range of the current antimicrobials. Bacteriophage therapy
is thus unique, and therefore would benefit from a dedicated
framework, which in many ways should differ from the cur-
rentmedicinal product (antibiotics) development andmarketing
pathways.
The EMA clearly stipulated during this workshop that none
of the regulations currently fit bacteriophage therapy adequately
(http://www.ema.europa.eu). Nevertheless, the French, Belgian
and Swiss competent authorities for medicines approved the
phage cocktails that will be tested in the PhagoBurn clinical
trial. Since this study benefits from EU funding, the authori-
ties were inclined to give ground to facilitate the approval of
the PhagoBurn phage cocktails. However, this step forward does
not offer a sustainable solution for future bacteriophage ther-
apy approaches. Clearly, two main (connected) barriers need to
be overcome. First, the regulatory pathway should be adapted
through the establishment of dedicated definitions and rules.
These rules are necessary to allow the field to tackle the sec-
ond barrier, which is the lack of public and private funding. As
mentioned in an earlier publication, both ‘preˆt a` porter’ (for co-
horts of patients) and ‘sur mesure’ (for individuals) approaches
can live side by side, as they will complement each other (Pirnay
et al. 2011). While the ‘preˆt a` porter’ approach may require
some long-term investments for production, the ‘sur mesure’
approach could be more rapidly implemented. Under the ini-
tiative of colleagues from the Queen Astrid Military Hospital in
Brussels, an article on the preparation of a bacteriophage solu-
tion, within the hospital laboratory, was published in 2009, and
recently broader consensus elaborated by 32 experts in the field
on the quality and safety requirements for bacteriophage prod-
ucts was published (Merabishvili et al. 2009; Pirnay et al. 2015).
Now it is time that political decision and public investment
make a difference. The debate is no longer about the pro and
cons of phage therapy, but rather about how we can move for-
ward for patients to benefit from this therapy. We are propos-
ing to set up dedicated public structures, National Reference
Centers (NRCs) for bacteriophage therapy. These NRCs will pilot
these treatments and put in place production of hospital-based
bacteriophage solutions, and application protocols that will en-
sure adequate product quality, patient safety and monitoring of
treatment efficacy. Even though bacteriophage therapy is rather
straightforward, matching bacteriophage to bacteria, advising
clinicians and keeping records of all treatments is crucial as this
information will be useful in setting up subsequent large clini-
cal trials, which could be sponsored by pharmaceutical compa-
nies. These NRCs should host or have access to a research team,
for isolating specific bacteriophages, as well as a bacteriophage
bank for providing long-term storage. From well-documented
clinical cases from the NRCs, relevant scientific questions will
emerge to dictate the paths that urgently need to be explored
and studied, instead of expecting basic science to run almost
unlimited investigations sincemanymolecular aspects of phage
therapy are still not understood. If we had waited for immunol-
ogy to be fully understood at the molecular level before the use
of vaccines, most of us would not be reading this paper! A simi-
lar approach has been recently proposed in the USA (Kutter et al.
2015) but in fine none of these proposals will ever be close to
reality if regulations are not adapted to bacteriophages, and not
the other way around.
The EMA workshop ended with the recommendation to pro-
mote additional clinical trials to further document how bacte-
riophages should best be applied in clinical practice. However,
without speedy adaptation of the medicinal product regulation
to support sustainable development of bacteriophage therapy,
this process will be unacceptably lengthy as established West-
ern pharmaceutical companies will not invest in the absence of
adequate rules and intellectual property protection. Meanwhile,
the list of patients requiring antimicrobial treatments will con-
tinuously increase (Witzenrath 2015). The time you read this,
10 persons died because no effective antibacterial treatmentwas
available. Which threshold of deaths will be reached before bac-
teriophages are allowed to be used to help save lives?
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